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Full clinical cases submission template 
 
TITLE OF CASE Do not include “a case report” 
From a fish tank injury to hospital haemodialysis: the serious consequences of drug 
interactions  
 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
 
We present the case of a 68 year old male admitted to hospital with severe acute kidney 
injury secondary to statin-induced rhabdomyolysis. Five weeks previously the patient 
commenced a course of clarithromycin for infection of a finger wound with Mycobacterium 
marinum. His current medications included Simvastatin whichSimvastatin that he continued 
along with clarithromycin. 
 
The severity of the acute kidney injury necessitated initial continuous venovenous 
haemofiltration followed by twelve haemodialysis sessions before a spontaneous 
improvement in renal function occurred.  
 
Statins are widely prescribed and we report this case to encourage increased vigilance in 
avoiding drug interactions known to increase the risk of statin-induced myopathy, including 
macrolide antibiotics, calcium channel antagonists and amiodarone.  The authors would also 
like to highlight recent guidance on atorvastatin as the statin of choice in patients with 
chronic kidney disease, and of the need for dose adjustment in those with estimated 
glomerular filtration rate less than 30mls/min/1.73m².1 
 
 
BACKGROUND Why you think this case is important – why did you write it up? 
 
In 2013 Prescription Cost Analysis revealed simvastatin to be the most commonly prescribed 
drug in England, with 39.9 million prescriptions dispensed that year2. Whilst the benefits of 
this drug in reducing cardiovascular risk are evident, and the side effects relatively rare, the 
large number of patients taking statins demands particular vigilance towards intolerance and 
drug interactions3.   
Myopathy and muscle disorders are the commonest side effect of statins, with 
rhabdomyolysis being the most serious3. We report this case to illustrate the morbidity 
associated with a case of statin-induced rhabdomyolysis, and to emphasise the on-going 
requirement for regular review of statin dosage and medication interactions.  
 
 
CASE PRESENTATION Presenting features, medical/social/family history 
 
A 68 year old man presented to hospital with a seven day history of increasing thigh pain 
and progressive proximal myopathy. Prior to this he was fit and independent. Past medical 
history included hypertension, hypercholesterolemia, chronic kidney disease stage 3a, 
gastro-oesophageal reflux disease and thrombocytopenia of unknown cause, which had been 
extensively investigated. As a hobby he kept tropical fish. 
 
Six months previously the patient had been referred to secondary care for a painful ulcer 
resulting from an injury that he had sustained whilst cleaning  his fish tank. The wound on 
his left index finger had failed to heal despite a three week antibiotic course. An ultrasound 
confirmed dactylitis and tenosynovitis. Two wound washouts were subsequently performed 
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three weeks apart. At At the second procedure the wound was found to contain locules of 
pus and Mycobacterium marinum, an atypical mycobacterium that is the cause of fish tank 
granuloma, was isolated on culture.  
 
An anti-tuberculous mycobacterial chemotherapy regime was commenced, consisting initially 
of rifampicin and ethambutol. On review in clinic five weeks prior to this admission, the 
patient had complained of nausea, sore eyes and a bitter taste in the mouth. His symptoms 
were attributed to rifampicin and this was therefore substituted with Clarithromycin; all other 
medications, including simvastatin 40mg daily, had remained unchanged.  
 
On admission physical examination demonstrated a painful proximal myopathy 
predominantly affecting the lower limbs with no evidence of compartment syndrome. He had 
a healing wound over the ulnar aspect of the distal interphalageal joint on his left index 
finger. Cardiovascular, respiratory and abdominal examination was unremarkable however 
the patient was anuric.  
INVESTIGATIONS If relevant 
 
Biochemistry revealed sodium 137mmol/L, potassium 7.0mmol/L, urea 39.8mmol/L, 
creatinine 702μumol/L and creatine kinase 216440 U/L [range 0-40].  
 
An abdominal ultrasound showed aa normal appearances of both kidneys with no evidence of 
hydronephrosis.  
 
Chest radiograph demonstrated mild left basal atelectasis but the lung fields were otherwise 
clear, with no evidence of pulmonary oedema.  
 
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
/  
 
TREATMENT If relevant  
 
The patient was admitted to thethe intensive care unitunit and placed on continuous 
venovenous haemofiltration (CVVHDF). Twenty-four hours later he transferred to the renal 
ward for on-going management of his acute kidney injury secondary to rhabdomyolysis.  
 
He remained an inpatient for 29 days, requiring ten further haemodialysis sessions whilst in 
hospital. Urine output increased gradually to 800mls per day, but then plateaued. Prior to 
discharge a tunnelled neck line was inserted for outpatient hospital haemodialysis.  
 
Simvastatin treatment was stopped immediately upon admission. Anti-tuberculous 
mycobacterial medications were also withheld. On review the left index finger wound was 
found to have healed with some residual scar tissue and restriction of movement around the 
proximal interphalangeal joint. The respiratory team advised permanent discontinuation of 
the clarithromycin and ethambutol course.  
 
OUTCOME AND FOLLOW-UP   
 
Following discharge the patient required on-ggoing haemodialysis but there was evidence of 
improving renal function with increasing urine output. Tt.Three weeks following discharge his 
urine output had increased to 1600 mls/day, creatine kinase had fallen to 161 U/l and 
dialysis was discontinued. At 3 months from initial presentation the patient remains dialysis-
independent. He remains under follow up due to persistent renal dysfunction 
(Cr>400µmol/l).  
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He was not restarted on statins. Anti-tuberculous mycobacterial medications were also 
withheld. On review the left index finger wound was found to have healed with some residual 
scar tissue and restriction of movement around the proximal interphalangeal joint. No 
further anti-tuberculous chemotherapy was prescribed.  
 
DISCUSSION Include a very brief review of similar published cases  
Although the incidence of rhabdomyolysis in patients taking statins is reported to be low 
(estimated 1.6 cases per 100 000 person-years)3, a systematic review of statin safety noted 
the importance of preventable cases in those patients taking CYP3A4 inhibitors4. Law et al 
demonstrated in cases of rhabdomyolysis linked to simvastatin, lovastatin or atorvastatin 
approximately 60% of patients were also taking a CYP3A4 inhibitor, such as a macrolide 
antibiotic, as in this case4.  
 
The risk of statin-induced myopathy is known to be dose-dependent5, and therefore drugs 
which inhibit the CYP34A pathway, through which simvastatin is metabolised, potentially 
increase exposure to the drug and its side-effects. The Medicines and Healthcare Products 
Regulatory Agency (MRHA) published updated guidance in 2012 highlighting that simvastatin 
is contra-indicated with macrolide antibiotics (erythromycin, clarithromycin, telithromycin) 
due to this risk profile6. Also contraindicated with simvastatin are: azole antifungals (e.g. 
itraconazole), HIV protease inhibitors (e.g. nelfinavir), nefazodone, ciclosporin, danazol 
andor gemfibrozil6. In addition, the dose of simvastatin must be restricted to 20mg 
maximum if the patient is taking either a calcium channel blocker (amlodipine, diltiazem, 
verapamil) or amiodarone6 (table 1).  
Recent data supports the association between a variant (rs4149056) in SLCO1B1 gene and 
simvastatin-induced myopathy7. The gene encodes for OATP1B1, which is an organic anion 
transporter that facilitates hepatic uptake of statins. People who have this variant have 
reduced transporter function and experience higher blood plasma levels of simvastatin for 
the same administered dose compared with normal metabolisers.  
The Clinical Pharmacogenetics Implementation Consortium have developed prescribing 
guidelines for Simvastatin in patients with the SLCO1B1 genotype advising lower doses and 
routine CK monitoring for patients known to be heterozygous or homozygous for the 
decreased-function allele8. Testing is not yet routinely available in the UK and the MRHA 
guidance is that if the genotype is known or can be tested this should be taken into account 
when prescribing high doses of simvastatin but suggest that alternative statins, that are not 
affected by the genotype, should be considered9. 
 
Data from The Study of the Effectiveness of Additional Reductions in Cholesterol and 
Homocysteine (SEARCH) collaborative group, which demonstrated the dose-dependent 
relationship between simvastatin and myopathy, has shown only a 6% reduction in major 
vascular events in patients taking 80mg of simvastatin compared to 20mg810. Therefore 
higher doses of simvastatin should be reserved for those with severe hypercholesterolaemia 
and high cardiovascular risk in whom the benefits outweigh the risks.  
 
Patients with renal impairment are at higher risk of myopathy, and thus their statin dose 
should be reduced accordingly. The patient presented here, known to have chronic kidney 
disease stage 3a, should ideally have been on atorvastatin 20mg at presentation, rather 
than simvastatin 40mg, in accordance with NICE guidance1. The statin should then have 
been suspended when the patient was prescribed a course of clarithromycin.  
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LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
 
 Simvastatin is contra-indicated with macrolide antibiotics due to increased myopathy 
risk  
 
 SLCO1B1 genotype can help to predict the risk of statin induced myopathy but testing 
is not yet routinely available in the UK. 
  
 A maximum dose of 20mg simvastatin should be used in patients also taking 
amlodipine, diltiazem, verapamil or amiodarone  
 
 Atorvastatin 20mg is the recommended starting agent for patients with chronic 
kidney disease where statins are indicated  
  
 Consider discussing higher statin doses with a nephrologist if the eGFR <30 
ml/min/1.73m² 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
Table 1. 
 
 
Drug interactions associated with increased risk of 
myopathy/rhabdomyolysis 
Interacting agents Prescribing recommendations 
Itraconazole 
Ketoconazole 
Posaconazole 
Erythromycin 
Clarithromycin 
Telithromycin 
HIV protease inhibitors (eg, nelfinavir) 
Nefazodone 
Ciclosporin 
Danazol 
Gemfibrozil 
Contraindicated with simvastatin 
Other fibrates (except fenofibrate) Do not exceed 10 mg simvastatin daily 
Amiodarone 
Amlodipine 
Verapamil 
Diltiazem 
Do not exceed 20 mg simvastatin daily 
Fusidic acid 
Patients should be closely monitored. 
Temporary suspension of simvastatin 
treatment may be considered. 
Grapefruit juice 
Avoid grapefruit juice when taking 
simvastatin 
 
Adapted from the Drug Safety Update August 20127 
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
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